EnVivo Pharma initiates Phase III trial for encenicline for Alzheimers
EnVivo Pharmaceuticals announced it has initiated COGNITIV AD, a Phase III clinical program evaluating its novel alpha-7 (alpha7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer�s disease (AD). The program is being conducted under a Special Protocol Assessment agreement with the FDA.
Patient dosing has begun in the 26-week trial, which is designed to evaluate the safety and efficacy of two fixed doses of encenicline compared to placebo in patients with mild to moderate AD who are currently receiving stable treatment with or have been previously treated with an acetylcholinesterase inhibitor.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.